These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33389453)

  • 1. Kynurenic Acid Protects Against Reactive Glial-associated Reductions in the Complexity of Primary Cortical Neurons.
    O'Reilly K; O'Farrell K; Midttun O; Rakovets Y; David-Bercholz J; Harkin A
    J Neuroimmune Pharmacol; 2021 Sep; 16(3):679-692. PubMed ID: 33389453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons.
    O'Farrell K; Fagan E; Connor TJ; Harkin A
    Eur J Pharmacol; 2017 Sep; 810():163-173. PubMed ID: 28688912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the kynurenine pathway in human glioma pathophysiology.
    Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
    PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
    Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
    Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
    Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
    Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenic Acid Prevents Cytoskeletal Disorganization Induced by Quinolinic Acid in Mixed Cultures of Rat Striatum.
    Pierozan P; Biasibetti-Brendler H; Schmitz F; Ferreira F; Pessoa-Pureur R; Wyse ATS
    Mol Neurobiol; 2018 Jun; 55(6):5111-5124. PubMed ID: 28840509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
    Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
    J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
    Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
    Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
    Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
    J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of d-amino acid oxidase in the production of kynurenine pathway metabolites from d-tryptophan in mice.
    Notarangelo FM; Wang XD; Horning KJ; Schwarcz R
    J Neurochem; 2016 Feb; 136(4):804-814. PubMed ID: 26661897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the immune-kynurenine pathway in treatment-resistant schizophrenia.
    Chen W; Tian Y; Gou M; Wang L; Tong J; Zhou Y; Feng W; Li Y; Chen S; Liu Y; Wang Z; Pan S; Zhang P; Huang J; Yang X; Li CR; Tian L; Hong LE; Tan Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Mar; 130():110926. PubMed ID: 38147973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of minocycline on indolamine 2, 3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia.
    Bahrami Z; Firouzi M; Hashemi-Monfared A; Zahednasab H; Harirchian MH
    Cytokine; 2018 Jul; 107():125-129. PubMed ID: 29246652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
    Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
    Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites.
    Jhamandas K; Boegman RJ; Beninger RJ; Bialik M
    Brain Res; 1990 Oct; 529(1-2):185-91. PubMed ID: 2149296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
    Fujigaki H; Yamamoto Y; Saito K
    Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
    Schwarcz R; Pellicciari R
    J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.